Home › Funds › Frazier Life Sciences Management, L.P. › DYN

Frazier Life Sciences Management, L.P. position in DYN

DYNE THERAPEUTICS INC · Health Care

Frazier Life Sciences Management, L.P. reported holding 3,153,082 shares of DYN (DYNE THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$70.0M, representing 1.53% of its reported portfolio and ranking #14 among its reported holdings. Frazier Life Sciences Management, L.P. has disclosed DYN holdings in 7 of the last 11 reported quarters, going back to Q4 2023.

Latest position (Q2 2026)3.15M sh
Reported value held$70.03M
Portfolio Weight1.53%
First reportedQ4 2023
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Frazier Life Sciences Management, L.P.'s DYN position evolved

Frazier Life Sciences Management, L.P. first disclosed a stake in DYN in Q4 2023 at 1,184,840 shares (US$15.8M). The position peaked in Q2 2026 at 3,153,082 shares, worth US$70.0M. Across 7 filings, Frazier Life Sciences Management, L.P. increased the stake 3 time(s), trimmed it 0 time(s) and left it unchanged 2 time(s). The most recent filing (Q2 2026) shows 3,153,082 shares valued at US$70.0M. Notable position changes include a 80% increase in Q3 2025 (shares rose 55% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2023 1.18M $15.76M New
Q1 2025 1.44M $15.10M New
Q2 2025 1.51M $14.34M Add
Q3 2025 2.72M $34.38M Add
Q4 2025 3.15M $61.67M Add
Q1 2026 3.15M $57.17M Hold
Q2 2026 3.15M $70.03M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About DYN and 13F data

DYN (DYNE THERAPEUTICS INC) is a Health Care company. 41 other funds we track also report a position in DYN — the largest reported positions include Atlas Venture Life Science Advisors, LLC (US$151.0M), TCG Crossover Management, LLC (US$102.5M), FCPM III SERVICES B.V. (US$85.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding DYN

All DYN fund holders →

FAQ

How long has Frazier Life Sciences Management, L.P. held DYN?

Frazier Life Sciences Management, L.P. has disclosed DYN holdings in 7 of the last 11 reported quarters, going back to Q4 2023.

What is Frazier Life Sciences Management, L.P.'s current position in DYN?

As of Q2 2026, Frazier Life Sciences Management, L.P. holds 3.15M shares of DYN (DYNE THERAPEUTICS INC), valued at $70.03M, representing 1.53% of its reported portfolio and ranking #14.

Has Frazier Life Sciences Management, L.P. been buying or selling DYN?

In the latest 13F filing (Q2 2026), Frazier Life Sciences Management, L.P. held unchanged its position in DYN. The position peaked in Q2 2026 at 3.15M shares.

Which other funds hold DYN?

Other major institutional holders of DYN include Atlas Venture Life Science Advisors, LLC, TCG Crossover Management, LLC, FCPM III SERVICES B.V., among 41 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.